Qualys Delivers Strong Quarter but Rating Downgraded on Valuation; Deep Value Thesis Holds

What happened

Qualys reported a robust quarter with 16% current billings growth, 11% revenue growth, and net dollar expansion improving to 105%, prompting management to raise full-year revenue guidance. Profitability remained exceptional, with 46% adjusted EBITDA margins and $703 million in cash, yet a Seeking Alpha analyst downgraded the stock, arguing the valuation no longer offers attractive upside. The DeepValue master report concurs that at ~$131 the stock is not deeply discounted, but still supports a 'Potential Buy' with a base-case fair value of $155 and an attractive entry zone down to $125. The thesis hinges on Enterprise TruRisk/ROC adoption driving sustained NDR above 106% and billings growth of 11–13%, which could justify a re-rating; without acceleration, shares may remain range-bound. While the downgrade introduces a more cautious near-term view, the fundamental outlook—durable high margins, recurring revenue, and heavy buybacks—remains intact, and the stock still offers a favorable risk/reward for patient investors.

Implication

The downgrade reflects a valuation call, not a deterioration in business quality, and the stock remains within the master report’s attractive entry zone ($125–$160). At ~$131, Qualys trades at ~22x EV/EBITDA and ~25x P/E, supported by 46% EBITDA margins and a net-cash balance sheet, providing a cushion if growth stays steady. Success in driving ROC/TruRisk adoption to lift NDR above 106% and billings growth to 11–13% would likely push shares toward the $155 base case or higher; failure to do so could leave the stock range-bound and warrant trimming. Disciplined buybacks and a clean balance sheet continue to enhance per-share value, making Qualys a high-quality compounder at a reasonable price. Investors should monitor Q4 2025 results and 2026 guidance for early signs of monetization of the AI-powered ROC and FedRAMP wins before increasing conviction.

Thesis delta

The Seeking Alpha downgrade introduces a more cautious near-term price target, but it aligns with the master report’s view that upside is limited above $160. The fundamental thesis—high-margin recurring revenue, net cash, and optionality on ROC/AI-driven expansion—is unchanged. However, the downgrade raises the bar for a re-rating, emphasizing that growth acceleration is necessary to justify a higher multiple.